Not currently recruiting at UCSF
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Summary
- Eligibility
- for people ages 18-99 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- AstraZeneca
- ID
- NCT06467357
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 620 study participants
- Last Updated